INTRODUCTION {#s1}
============

Endothelin-1 (ET-1) belongs to a family of 21-amino acid residue peptides is expressed, in different patterns, in various tissues and cells[@r1], [@r2]^)^ ([Fig. 1A](#fig_001){ref-type="fig"}Fig. 1.Schematic representation of mechanisms of endothelin-1-related pain in nanophysiotherapy. ETs, endothelins; IL-1/-2; interleukin-1 and -2; AngII, angiotensin II; GF, growth factor; ANP, atrial natriuretic peptide; BNP, brain natriuretic peptide; CNP, C-type natriuretic peptide; NH~2~, amino group; COOH, carboxyl group; C, cysteine; S, serine; L, leucine; M, methionine; D, aspartic acid; K, lysine; E, glutamic acid; V, valine; Y, tyrosine; F, phenylalanine; H, histidine; I, isoleucine; W, tryptophan; ET-1, endothelin-1; ET~A~R, subtype A of endothelin receptor; PKC, protein kinase C; Gq, subtype q of trimeric GTP-binding protein; PIP~2~, phosphatidylinositol 4,5-bisphosphate; PLC, phospholipase C; DAG, diacylglycerol; IP~3~, inositol 1,4,5-triphosphate; \[Ca^2+^\]~i~, intracellular or cytosolic Ca^2+^; Ik, delayed rectifier K^+^ currents; TRPV1, transient receptor potential cation channel subfamily V member 1 also known as the the vanilloid receptor 1; UPMR, unique plasma membrane-bound receptor; TTX-R I~Na~, tetrodotoxin-resistant voltage-gated Na^+^ currents; MAPKs, mitogen-activated protein kinases.). ET-1 plays a role in controlling muscle contraction, cell proliferation, and cell activity[@r1], [@r2]^)^. It has been reported that the protein kinase C (PKC) pathway, mitogen-activated protein kinases (MAPKs) pathway, and myosin light chain kinase (MLCK)-activated pathway contribute to ET-1-induced contraction[@r1], [@r2]^)^. In particular, DOCA-dependent hypertension is recognized as an important component of MAPK-related ET-1[@r1]^)^. ET-1 can be released in response to chemical or physical stimuli, such as in response to the vasoactive amine norepinephrine, hypoxic stimulation, and ischemia[@r2], [@r3]^)^. In normal physiology conditions, ET-1 is expressed at a low level in plasma[@r4], [@r5]^)^. It was reported that the level of plasma ET-1 is increased in hypertension and myocardial infarction and that it can be used as a biomarker of cardiovascular disorders[@r4], [@r5]^)^. Furthermore, ET-1 plays a role in cell growth, apoptosis, muscle contraction, and inflammation through MAPK activations[@r1], [@r2]^)^. These MAPKs include extracellular signal-regulated protein kinase-1 and kinase-2 and the p38 mitogen-activated protein. Studies have confirmed that these are related to ET-1 in eukaryotic cells[@r1], [@r2]^)^. Meanwhile, studies have also reported that the MAPK pathway plays an important part in the mechanism of hyperalgesia and allodynia[@r6], [@r7]^)^. ET-1 is produced and secreted from the dorsal root ganglion, spinal cord, and peripheral nerves[@r8]^)^. ET-1 acts as a pain inhibitor in the central nervous system, whereas it can cause painful sensitivity, as hyperalgesia and allodynia, in the peripheral nerve system[@r9],[@r10],[@r11]^)^. However, the mechanism underlying ET-1- and MAPK-related pain is still unknown. The purpose of this review was to elucidate the ET-1- and MAPK-related pain mechanism and to contribute to future studies of pain nanophysiotherapy from the perspective of nanoparticle-associated signal transduction ([Fig. 1B](#fig_001){ref-type="fig"}).

1. Mechanisms of endothelin-1-related pain for nanophysiotherapy
----------------------------------------------------------------

ET-1 is present in the brain, spinal cord, sympathetic ganglia, and spinal ganglion in mammals, including humans, and it is thought to play a significant part in the pain signaling system[@r8], [@r10], [@r12], [@r13]^)^. ET-1 produces different reactions in the central and peripheral nervous systems[@r10], [@r11], [@r13]^)^. Injection of ET-1 into the periaqueductal gray area and the spinal cord results in an antinociceptive effect, whereas injection into the peripheral nervous system results in hyperalgesia and pain reactions[@r10], [@r11], [@r13], [@r14]^)^. ET-1 is also produced in numerous cells, including inflammatory and cancer cells. According to some reports, excessive levels of ET-1 are released following skin damage[@r15], [@r16]^)^. ET-1 increases sensitivity to harmful chemical stimuli such as capsaicin[@r17], [@r18]^)^. Meanwhile, PKC induces the creation of action potential in neuron of pain transmission[@r19],[@r20],[@r21],[@r22]^)^. ET-1 appears to be involved in the activation of PKC[@r23], [@r24]^)^ ([Fig. 1B](#fig_001){ref-type="fig"}). The ET-1 receptor is activated during activation of the ET-1-induced polymodal-C nociceptor[@r25]^)^. The catalytic response of the trimeric guanosine triphosphate-binding protein by receptor activation can activate phospholipase C[@r2], [@r26]^)^ ([Fig. 1B](#fig_001){ref-type="fig"}). Although phospholipase C shows tissue specificity, it promotes an influx of extracellular Ca^2+^ from a unique plasma membrane-bound receptor and voltage-gated Ca^2+^ channel through the creation and activation of inositol 1,4,5-triphosphate[@r2], [@r27], [@r28]^)^ ([Fig. 1B](#fig_001){ref-type="fig"}). The increased intracellular Ca^2+^ in response to the ET-1 stimulus transmits pain signals to the primary sensory area, leading to amplification of tetrodotoxin-resistant voltage-gated Na^+^ currents[@r10], [@r16], [@r29]^)^ ([Fig. 1B](#fig_001){ref-type="fig"}). Diacylglycerol induced by the activation of ET-1 also activates PKC[@r18], [@r29]^)^. The activation mechanism is comprised of a translocation process that inactivates PKC present in the cytoplasm transfer to cell membrane[@r2], [@r18], [@r30]^)^. However, more study is necessary to elucidate the pain mechanism of ET-1 using the transcutaneous electrical nerve stimulation or interferential current treatment from the perspective of nanoparticle-associated signal transduction ([Fig. 1B](#fig_001){ref-type="fig"}).

2. Mitogen-activated protein kinases and pain mechanisms for nanophysiotherapy
------------------------------------------------------------------------------

There are two types of pain mechanisms that induce inflammation and hyperalgesia. The first is the signal transmission pathway through adenylate cyclase (also called adenylyl cyclase, which is a 12-transmembrane protein)-linked protein kinase A, and the second is the transmission pathway through phospholipase C-related PKC[@r31],[@r32],[@r33]^)^. Furthermore, previous studies have reported that hyperalgesia is involved in the MAPK signal pathway in addition to the protein kinase A and PKC pathway[@r7], [@r34],[@r35],[@r36]^)^. Hyperalgesia can be induced by three sources: an injection of substance P into the dura mater, an instillation injection of capsaicin in the large intestine, and the release of cytokines, such as interleukin-1β[@r7], [@r34]^)^. However, the exact mechanism underlying allodynia is not known. It has been suggested that a severed A-β fiber terminal regenerated by lamina of Rexed II or trans-synaptic degeneration in the spinal dorsal horn may contribute to the development of allodynia[@r37], [@r38]^)^. Allodynia induced by sympathetic nerve excitement has been attributed to noradrenergic sprouting around the dorsal root ganglion or nerve fibers in damaged peripheral nerves[@r39], [@r40]^)^. Other studies have reported that the peripheral nerve terminal and an increase in the spontaneous discharge in dorsal root ganglion cells create allodynia[@r41], [@r42]^)^. In particular, studies have emphasized the importance of MAPK because the MAPK pathway is involved in allodynia in the same way as spinal nerve ligation[@r6], [@r43]^)^. More study is needed on MAPK-related pain control using physical factors for pain control from the perspective of nanophysiotherapy[@r44],[@r45],[@r46],[@r47]^)^ ([Fig. 1B](#fig_001){ref-type="fig"}).
